by Fadi Agour | Jan 15, 2025 | Uncategorized
The process of generating and managing workers’ compensation leads has undergone a significant transformation with the advent of technology. Modern tools and software solutions are now indispensable in streamlining operations, improving lead quality, and...
by Fadi Agour | Jan 9, 2025 | Uncategorized
Mass tort cases often involve a large number of claimants seeking justice for harm caused by a common defendant, such as pharmaceutical companies or manufacturers. For attorneys specializing in these cases, building a robust referral network can significantly boost...
by Fadi Agour | Dec 26, 2024 | Uncategorized
The legal landscape surrounding Depo-Provera litigation is complex and still evolving, but understanding key trends and challenges can help legal professionals navigate this landscape with greater confidence. Depo-Provera, a contraceptive injection that has been on...
by Fadi Agour | Dec 26, 2024 | Uncategorized
A Growing Need for High-Quality Roundup Claimants As Roundup litigation continues to unfold, the volume of claims related to its potential link to Non-Hodgkin’s Lymphoma (NHL) continues to grow. This has led to an increasing demand for claimant leads that are not...
by Fadi Agour | Dec 17, 2024 | Uncategorized
In today’s fast-paced digital landscape, staying relevant requires meticulous planning and consistency. This is where a content calendar becomes a game-changer. A content calendar is a strategic tool that helps businesses, creators, and marketers plan content topics,...
by Fadi Agour | Dec 12, 2024 | Uncategorized
By Fadi Agour, J.D. · Updated November 10, 2026 · Facts last reviewed November 10, 2026 Short answer: Oxbryta litigation is small, individual and moving toward settlement. Pfizer pulled the sickle cell drug from every market on September 25, 2024. The cases sit mostly...
Recent Comments